PA
MRNA icon

Parallel Advisors’s Moderna MRNA Stock Holding History

Parallel Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Buy
4,881
+1,537
+46% +$71.7K ﹤0.01% 1051
2025
Q4 		$98.6K Sell
3,344
-1,517
-31% -$41.2K ﹤0.01% 1476
2025
Q3 		$126K Buy
4,861
+343
+8% +$9.57K ﹤0.01% 1299
2025
Q2 		$125K Buy
4,518
+115
+3% +$3.03K ﹤0.01% 1250
2025
Q1 		$125K Buy
4,403
+451
+11% +$16K ﹤0.01% 1186
2024
Q4 		$164K Buy
3,952
+605
+18% +$28.9K ﹤0.01% 1014
2024
Q3 		$224K Sell
3,347
-902
-21% -$82.8K 0.01% 877
2024
Q2 		$505K Sell
4,249
-1,163
-21% -$147K 0.01% 532
2024
Q1 		$577K Buy
5,412
+1,624
+43% +$164K 0.02% 493
2023
Q4 		$377K Sell
3,788
-1,922
-34% -$162K 0.01% 577
2023
Q3 		$590K Sell
5,710
-250
-4% -$27.9K 0.02% 416
2023
Q2 		$724K Sell
5,960
-508
-8% -$67.8K 0.02% 378
2023
Q1 		$993K Sell
6,468
-323
-5% -$53.3K 0.03% 310
2022
Q4 		$1.22M Buy
6,791
+209
+3% +$34.2K 0.05% 226
2022
Q3 		$778K Sell
6,582
-771
-10% -$117K 0.04% 285
2022
Q2 		$1.05M Sell
7,353
-413
-5% -$59K 0.05% 237
2022
Q1 		$1.36M Buy
7,766
+399
+5% +$67.2K 0.05% 221
2021
Q4 		$1.87M Buy
7,367
+1,221
+20% +$357K 0.07% 182
2021
Q3 		$2.37M Buy
6,146
+2,787
+83% +$1.03M 0.1% 149
2021
Q2 		$789K Buy
3,359
+67
+2% +$12K 0.03% 293
2021
Q1 		$431K Buy
3,292
+1,703
+107% +$247K 0.02% 389
2020
Q4 		$166K Buy
1,589
+604
+61% +$61.1K 0.01% 648
2020
Q3 		$70K Buy
985
+287
+41% +$20K ﹤0.01% 920
2020
Q2 		$44K Buy
698
+52
+8% +$2.85K ﹤0.01% 1093
2020
Q1 		$19K Sell
646
-1,496
-70% -$34.4K ﹤0.01% 1337
2019
Q4 		$42K Buy
2,142
+142
+7% +$2.52K ﹤0.01% 1095
2019
Q3 		$32K Sell
2,000
-1,200
-38% -$17.7K ﹤0.01% 1161
2019
Q2 		$47K Sell
3,200
-6,950
-68% -$149K ﹤0.01% 931
2019
Q1 		$207K Buy
+10,150
New +$188K 0.02% 392

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallel Advisors's MRNA Position: Q1 2026 in Review

Parallel Advisors increased its Moderna (MRNA) stake by 46% in Q1 2026, buying an estimated $71.7K and bringing the position to 4,881 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

Parallel Advisors first reported a position in MRNA in Q1 2019 and has held it in 29 quarters since. The position peaked at $2.37M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Parallel Advisors held 4,881 shares of Moderna worth $248K as of Q1 2026.
  • Parallel Advisors bought 1,537 Moderna shares in Q1 2026, an estimated $71.7K.
  • Moderna made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1051 holding.
  • Parallel Advisors first reported a position in Moderna in Q1 2019 and has held it in 29 quarters since.
  • Parallel Advisors's Moderna position peaked at $2.37M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.